GlassScriptPhysician profile
Shelton Hager
NPI 1407859796
$14,296.11
in general payments reported to CMS, 2019-2025
57 companies · $1,350 in 2025
The $1,350 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,207 · 2020: $2,049 · 2021: $2,994 · 2022: $2,491 · 2023: $1,829 · 2024: $1,376 · 2025: $1,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,555.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,789.76 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,538.82 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,335.46 | 2021-2025 | |
| Pfizer INC. | $1,159.22 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,071.03 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $600.36 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $542.68 | 2019-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $464.99 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $459.05 | 2019-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $436.12 | 2021-2025 | |
| Lilly USA, LLC | $405.94 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $391.78 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $382.51 | 2019-2025 | |
| Allergan, INC. | $367.57 | 2019-2021 | |
| Amarin Pharma, INC. | $360.79 | 2019-2022 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelton Hager listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.